A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen Under Fasted Conditions in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2018
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 16 Oct 2018 Status changed from recruiting to completed.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 21 Aug 2018 New trial record